Kết quả bước đầu phác đồ paclitaxel – carboplatin trong điều trị ung thư phổi không tế bào nhỏ giai đoạn muộn kháng thuốc EGFR tyrosine kinase thế hệ 1, 2

Evaluating the response rates and analyzing affected factors to response rate of paclitaxel – cisplatin chemotherapy for the treatment of advanced/ metastatic non-small cell lung cancer acquired resistance to EGFR TKIs first- and second-generations without presence of T790M mutation at National Cancer Hospital from 01/2017 to 05/2022. Patients and method: Retrospective and prospective analysis of 55 patients with advanced/ metastatic non-small cell lung carcinoma acquired resistance to EGFR TKIs first- and second-generations without presence of T790M mutation at National Cancer Hospital from 01/2017 to 05/2022. Results: Most of patients were received of 100% full-dose chemotherapy. Mean cycles were 5.7. Of 55 patients, 26 achieved a partial response (47,3%), no complet response was observed. Disease control rate was 74.5%. performance status ECOG 0 had a higher response rate compared to ECOG 1. Symptoms relief was reported in 63.6% patient with chemotherapy. Conclusion: Paclitaxel – carboplatin chemotherapy is an appropriate regimen choice for patients with non-small cell lung cancer after acquired resistance to tyrosine kinase without presence of T790M mutation.